Πέμπτη 20 Δεκεμβρίου 2018

FDA Approves Merck's KEYTRUDA® (pembrolizumab) for the Treatment of Adult and Pediatric Patients with Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma, a Rare Form of Skin Cancer | Antibodies | News Channels - PipelineReview.com

FDA Approves Merck's KEYTRUDA® (pembrolizumab) for the Treatment of Adult and Pediatric Patients with Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma, a Rare Form of Skin Cancer | Antibodies | News Channels  PipelineReview.com

FDA Approves Merck's KEYTRUDA® (pembrolizumab) for the Treatment of Adult and Pediatric Patients with Recurrent Locally Advanced or Metastatic Merkel ...



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2ExuOUC

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.